$0.84 EPS Expected for MEDNAX Inc (MD) This Quarter

Brokerages expect MEDNAX Inc (NYSE:MD) to post $0.84 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for MEDNAX’s earnings. The lowest EPS estimate is $0.83 and the highest is $0.85. MEDNAX posted earnings of $1.00 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 16%. The company is expected to announce its next earnings results on Tuesday, February 6th.

On average, analysts expect that MEDNAX will report full-year earnings of $3.31 per share for the current financial year, with EPS estimates ranging from $3.29 to $3.32. For the next year, analysts forecast that the company will report earnings of $3.54 per share, with EPS estimates ranging from $3.35 to $3.65. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for MEDNAX.

MEDNAX (NYSE:MD) last issued its earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.87. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The company had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. During the same quarter last year, the firm earned $1.09 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis.

Several research analysts recently weighed in on the stock. Jefferies Group reissued a “hold” rating and set a $46.00 price objective on shares of MEDNAX in a research note on Tuesday, October 3rd. Citigroup reduced their price objective on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. SunTrust Banks set a $55.00 price objective on shares of MEDNAX and gave the stock a “hold” rating in a research note on Thursday, December 21st. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, Robert W. Baird lifted their price objective on shares of MEDNAX from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company. MEDNAX has an average rating of “Hold” and an average target price of $53.82.

In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the sale, the insider now directly owns 35,569 shares in the company, valued at approximately $1,834,649.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cesar L. Alvarez sold 10,668 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the sale, the director now owns 44,215 shares in the company, valued at $1,883,116.85. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Prudential Financial Inc. raised its holdings in shares of MEDNAX by 976.9% in the third quarter. Prudential Financial Inc. now owns 641,057 shares of the company’s stock valued at $27,642,000 after purchasing an additional 581,527 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of MEDNAX in the third quarter valued at approximately $695,000. Nomura Holdings Inc. acquired a new stake in shares of MEDNAX in the second quarter valued at approximately $347,000. Point72 Asset Management L.P. raised its holdings in shares of MEDNAX by 71.7% in the third quarter. Point72 Asset Management L.P. now owns 132,700 shares of the company’s stock valued at $5,722,000 after purchasing an additional 55,400 shares during the last quarter. Finally, Advisor Group Inc. raised its holdings in shares of MEDNAX by 41.9% in the third quarter. Advisor Group Inc. now owns 8,361 shares of the company’s stock valued at $359,000 after purchasing an additional 2,468 shares during the last quarter. Hedge funds and other institutional investors own 98.43% of the company’s stock.

MEDNAX (NYSE:MD) traded up $1.72 during trading on Friday, reaching $53.52. 727,474 shares of the company traded hands, compared to its average volume of 945,308. MEDNAX has a twelve month low of $40.56 and a twelve month high of $72.13. The company has a market cap of $4,928.14, a price-to-earnings ratio of 18.91, a price-to-earnings-growth ratio of 1.58 and a beta of 0.39. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://weekherald.com/2018/01/19/0-84-eps-expected-for-mednax-inc-md-this-quarter.html.

About MEDNAX

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply